NPM1突变且欧洲白血病网预后良好组急性髓系白血病:基于可测量残留病的抢先干预后结局
该研究分析110例诱导化疗后达完全缓解的ELN预后良好组NPM1突变急性髓系白血病患者,2年累积复发率为17%、总生存率81.5%、无白血病生存率82%。46例因分子学失败或血液学复发接受额外治疗,其2年总生存率66%,分子学失败者86%高于血液学复发者42%(P=0.002)。首次巩固后MRD比值0.05为界,2年分子学无白血病生存率分别为77%和40%。
要点
- ELN预后良好组NPM1突变AML患者2年累积复发率17%、总生存率81.5%、无白血病生存率82%。
- 46例因分子学失败或血液学复发接受额外治疗者2年总生存率66%。
- 首次巩固后MRD比值0.05为界,2年分子学无白血病生存率分别为77%和40%。
核心结论
- 基于可测量残留病的抢先干预使ELN预后良好组NPM1突变急性髓系白血病患者获得良好结局。
研究设计与样本
- 研究纳入110例诱导化疗后达完全缓解的欧洲白血病网预后良好组NPM1突变急性髓系白血病患者,分析基于可测量残留病的抢先干预。
主要发现
- 2年累积复发率为17%,总生存率为81.5%,无白血病生存率为82%。
- 46例因分子学失败(n=33)或血液学复发(n=13)接受额外治疗,2年分子学无白血病生存率为61%,2年分子学失败累积发生率为38%。
- 这46例患者2年总生存率为66%,分子学失败者86% vs 血液学复发者42%(P=0.002)。
- 首次巩固后MRD比值(NPM1mut/ABL1×100)截断值0.05以下和以上患者的2年分子学无白血病生存率分别为77%和40%。
关键数值与推荐
- 首次巩固后MRD比值(NPM1mut/ABL1×100)截断值0.05以下患者的2年分子学无白血病生存率为77%,0.05以上者为40%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the European LeukemiaNet favourable risk category, allogeneic haematopoietic stem cell transplantation (alloSCT) is not indicated in first complete remission for patients with acute myeloid leukaemia (AML) with NPM1 mutations (ELNfav NPM1 AML), although a proportion of these patients will relapse. Given the prognostic importance of measurable residual disease (MRD), CETLAM-12 considered a pre-emptive intervention in patients with molecular failure (MF). We analyzed 110 ELNfav NPM1 AML patients achieving complete remission (CR) after induction chemotherapy. Two-year cumulative incidence of relapse (CIR), overall survival (OS) and leukaemia-free survival (LFS) were 17%, 81·5% and 82%, respectively. Forty-six patients required additional therapy for MF (n = 33) or haematological relapse (HemR; n = 13), resulting in a molecular LFS (molLFS) and a cumulative incidence of MF at two years of 61% and 38% respectively. Two-year OS for these 46 patients was 66%, with a different outcome between patients with MF (86%) and HemR (42%) (P = 0·002). Quantitative NPM1 detection at different timepoints was predictive of molLFS; an MRD ratio (NPM1mut/ABL1 × 100) cut-off of 0·05 after first consolidation identified two cohorts with a two-year molLFS of 77% and 40% for patients below and above 0·05, respectively. In conclusion, MRD-based pre-emptive intervention resulted in a favourable outcome for ELNfav NPM1 AML patients.
引用
- Bataller A, Oñate G, Diaz-Beyá M, et al. Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. Br J Haematol. 2020. PMID: 32510599. doi:10.1111/bjh.16857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。